Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged \>= 18 years at time of consent.~* Have a diagnosis of Psoriatic arthritis (PsA) of \>= 6 months~* Meet the Classification Criteria of PsA (CASPAR) at time of screening~* Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).~* Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and required~* Must not have taken a biologic Tumour Necrosis Factor Inhibitor~* Must have 3 or more swollen joints AND 3 or more tender joints~* Must have active psoriasis skin lesions~Exclusion Criteria:~* Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the exception of nail psoriasis which is allowed~* Pregnant or breast feeding, females of child-bearing potential not using highly effective contraception~* New York Heart Association Class III and IV congestive heart failure~* History of hypersensitivity or infusion reaction to biologic agents~* Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 5 mgBID x 12 months (Type: EXPERIMENTAL): None
- Tofacitinib 10 mg BID x 12 months (Type: EXPERIMENTAL): None
- Adalimumab 40 mg q2 weeks x 12 months (Type: ACTIVE_COMPARATOR): None
- Placebo x3 months, then tofacitinib 5 mg BIDx 9 months (Type: PLACEBO_COMPARATOR): None
- Placebo x 3 months, then tofacitinib 10 mg BID x 9 months (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).